Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Completed 4Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1

Interventions

pembrolizumab 30Cisplatin 20Carboplatin 20Paclitaxel 18Dexamethasone 15Pemetrexed 13Nivolumab 13Ipilimumab 12Fluorouracil 11Cyclophosphamide 11Gemcitabine 10Trastuzumab 9Docetaxel 9Cytarabine 9daratumumab 8atezolizumab 8Rituximab 8Capecitabine 8Lenalidomide 7Doxorubicin 7zanubrutinib 6Prednisone 6Daunorubicin 6Bortezomib 6venetoclax 5trametinib 5nilotinib 5ibrutinib 5fludarabine 5dabrafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Has announcements × enzalutamide × Clear all
NCT02003924 2026-01-27

PROSPER

Pfizer

Phase 3 Completed
1,401 enrolled 25 charts 1 FDA
Genitourinary

Prostatic Neoplasms

NCT02677896 2025-10-24

ARCHES

Astellas Pharma Inc

Phase 3 Completed
1,150 enrolled 23 charts 1 FDA
Genitourinary

Metastatic Hormone Sensitive Prostate Cancer

NCT02975934 2025-07-25

TRITON3

pharmaand GmbH

Phase 3 Completed
405 enrolled 34 charts 1 FDA
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT02987543 2023-10-06

Study of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

AstraZeneca

Phase 3 Completed
387 enrolled 16 charts 1 FDA
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡